ZLAB Zai Lab Ltd. Sponsored ADR

Zai Lab Announces Presentations at June Conferences

Zai Lab Announces Presentations at June Conferences

SHANGHAI and SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that the Company will be presenting at the following upcoming virtual conferences in June. Details of the virtual conferences are as follows:

Jefferies Global Healthcare Conference 2020

Presentation: Tuesday, June 2, 2020 at 3:00 p.m. EDT

Presenter: Dr. Samantha Du, Founder, Chairperson & Chief Executive Officer

Goldman Sachs 41st Annual Global Healthcare Conference

Presentation: Thursday, June 11, 2020 at 9:40 a.m. EDT

Presenter: Dr. Samantha Du, Founder, Chairperson & Chief Executive Officer

JP Morgan China Investor Conference

Panel Discussion: Wednesday, June 24, 2020 at 8:00 a.m. CST

Presenter: Dr. Samantha Du, Founder, Chairperson & Chief Executive Officer

Live webcasts of the conferences will be available under "Events & Presentations” in the “Investors Relations” section of Zai Lab’s website. Archived replays will be available for 90 days following the event.

About Zai Lab

Zai Lab (NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

For additional information about the company, please visit or follow us at .

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab

Billy Cho, CFO

01

Media: Ryo Imai / Robert Flamm, Ph.D.

Burns McClellan, on behalf of Zai Lab

212-213-0006 ext. 315 / 364

/

Investors: Pete Rahmer / Mike Zanoni

Endurance Advisors, on behalf of Zai Lab

415-515-9763 / 610-442-8570

/

EN
27/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zai Lab Ltd. Sponsored ADR

Zai Lab Limited: 2 directors

Two Directors at Zai Lab Limited sold 12,544 shares at between 18.713USD and 18.860USD. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...

 PRESS RELEASE

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corp...

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates Total product revenue of $69.2 million for the third quarter of 2023, representing 22% y-o-y growth; 27% y-o-y growth at constant exchange rate (CER)VYVGART® (efgartigimod alfa injection) achieved $4.9 million sales since its commercial launch in September in ChinaStrong balance sheet with a cash position of $822.2 million as of September 30, 2023, compared to $876.4 million as of June 30, 2023Company to host conference call and webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CAMBRIDGE, Mas...

 PRESS RELEASE

Zai Lab Announces Participation in November Investor Conferences

Zai Lab Announces Participation in November Investor Conferences SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023: Jefferies London Healthcare ConferenceFireside Chat: Wednesday, November 15th at 1:00 p.m. GMTLocation: London 6th Annual Evercore ISI HealthCONx ConferenceFireside Chat: Wednesday, November 29th at 1:45 p.m. ESTLocation: Miami A live webcast of the presentations will b...

 PRESS RELEASE

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Co...

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023 - Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2023 and recent corporate updates, after the closing of the U.S. equity markets on November 7, 2023. The Company will host a live conference call and webcast on November 8, 2023, at 8:00 a.m. ET. Conference Ca...

 PRESS RELEASE

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa...

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of patients with chronic inflammatory demyelinatin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch